Shared on31 Jul 25Fair value Decreased 21%
Despite a higher net profit margin, Oscar Health's sharply lower future P/E ratio indicates reduced growth expectations, prompting analysts to cut their price target from $14.24 to $11.29. What's in the News Oscar Health revised 2025 guidance: expects total revenue of $12.0–$12.2 billion and a loss from operations of $200–$300 million.
Shared on30 Apr 25Fair value Decreased 3.79%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 8.09%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 2.87%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 30%
AnalystConsensusTarget has decreased revenue growth from 18.0% to 13.7%, increased profit margin from 3.0% to 4.2% and decreased future PE multiple from 18.4x to 12.4x.